<DOC>
	<DOCNO>NCT00160225</DOCNO>
	<brief_summary>This study evaluate end treatment effect Daglutril compare placebo top losartan .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Daglutril Compared Placebo Top Losartan Type 2 Diabetics With Overt Nephropathy Well Controlled Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>treat optimize dose losartan ( constant dose least four week randomization throughout whole study period ) least four week urinary albumin excretion ≥ 20 &lt; 1000 µg/min sit systolic/diastolic blood pressure ( SBP/DBP ) &lt; 140/90 mmHg end placebo runin phase know secondary hypertension decompensated congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>blood pressure , diabetic nephropathy , proteinuria</keyword>
</DOC>